VP
ELEV

venBio Partners’s Elevation Oncology ELEV Stock Holding History

venBio Partners’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,434,255
Closed -$6.57M – 7
2024
Q2 		$6.57M Sell
2,434,255
-261,878
-10% -$986K 2.84% 6
2024
Q1 		$13.8M Sell
2,696,133
-218,122
-7% -$707K 4.91% 5
2023
Q4 		$1.56M Hold
2,914,255
– – 0.23% 6
2023
Q3 		$1.93M Hold
2,914,255
– – 0.55% 7
2023
Q2 		$4.43M Buy
2,914,255
+1,047,916
+56% +$2.76M 1.6% 6
2023
Q1 		$3.55M Hold
1,866,339
– – 1.97% 6
2022
Q4 		$1.77M Hold
1,866,339
– – 0.55% 7
2022
Q3 		$2.11M Hold
1,866,339
– – 0.49% 8
2022
Q2 		$2.61M Sell
1,866,339
-741,828
-28% -$1.86M 0.74% 8
2022
Q1 		$6.57M Hold
2,608,167
– – 1.46% 9
2021
Q4 		$15.7M Hold
2,608,167
– – 2.83% 7
2021
Q3 		$20.3M Hold
2,608,167
– – 2.02% 6
2021
Q2 		$35.4M Buy
+2,608,167
New +$32.2M 4.18% 5

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

venBio Partners's ELEV Position: Q3 2024 in Review

venBio Partners sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 2,434,255 shares — an estimated $6.57M sold.

venBio Partners first reported a position in ELEV in Q2 2021 and held it in 13 quarters. The position peaked at $35.4M in Q2 2021. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • venBio Partners reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • venBio Partners sold 2,434,255 Elevation Oncology shares in Q3 2024, an estimated $6.57M.
  • venBio Partners first reported a position in Elevation Oncology in Q2 2021 and held it in 13 quarters.
  • venBio Partners's Elevation Oncology position peaked at $35.4M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on venBio Partners's 13F filing for Q3 2024, filed 14 Nov 2024.